Immuno-Oncology

Takeda Strikes $11 Billion-Plus Oncology Deal With Innovent, Pays $1.2 Billion Upfront

The Japanese drugmaker turns to Chinese-built cancer medicines to replenish its oncology pipeline after recent patent losses.